Physician profile
Maxen Baumgardner
NPI 1851414981
$1,392.95
in general payments reported to CMS, 2019-2025
10 companies · $178 in 2025
The $178 reported for 2025 was more than what 80% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2021: $50.09 · 2022: $251 · 2023: $260 · 2024: $417 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.05 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $398.12 | 2019-2024 | Andexxa |
| Abbvie INC. | $258.07 | 2021-2024 | Teflaro, Dalvance |
| Csl Behring | $205.40 | 2023-2024 | Kcentra |
| Mallinckrodt Hospital Products INC. | $146.20 | 2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $113.01 | 2022 | |
| Allergan, INC. | $100.14 | 2019 | |
| Mindray Ds USA, INC. | $81.26 | 2023-2025 | Te X, Te7 Max |
| Karl Storz Endoscopy-America | $58.09 | 2024 | |
| Gilead Sciences, INC. | $20.58 | 2022 | |
| Bard Access Systems, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxen Baumgardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.